● CLOSED
SPY769.60
8.41 (-1.08%)
|
QQQ728.95
14.62 (-1.97%)
|
AAPL342.96
+1.69 (+0.50%)
|
MSFT533.69
9.76 (-1.80%)
|
TSLA367.16
8.07 (-2.15%)
|
NVDA221.30
7.22 (-3.16%)
|
AMZN254.08
4.50 (-1.74%)
|
GOOGL347.64
6.14 (-1.74%)
|
BTC81,508
+0.00 (+-2.45%)
|
ETH2,418
+0.00 (+-3.90%)
|
SOL104.29
+0.00 (+-3.26%)
|
BNB729.10
+0.00 (+-2.11%)
|
XRP1.33
+0.00 (+-3.49%)
|
ADA0.2297
+0.00 (+-3.74%)
|
SPY769.60
8.41 (-1.08%)
|
QQQ728.95
14.62 (-1.97%)
|
AAPL342.96
+1.69 (+0.50%)
|
MSFT533.69
9.76 (-1.80%)
|
TSLA367.16
8.07 (-2.15%)
|
NVDA221.30
7.22 (-3.16%)
|
AMZN254.08
4.50 (-1.74%)
|
GOOGL347.64
6.14 (-1.74%)
|
BTC81,508
+0.00 (+-2.45%)
|
ETH2,418
+0.00 (+-3.90%)
|
SOL104.29
+0.00 (+-3.26%)
|
BNB729.10
+0.00 (+-2.11%)
|
XRP1.33
+0.00 (+-3.49%)
|
ADA0.2297
+0.00 (+-3.74%)
|
Invest Daily
ACTIVO AHORA

Únete al Debate de $LLY

Inversores reales compartiendo análisis en tiempo real

5
Publicaciones
1
Inversores
Pulso de la Comunidad
Alcista 40%20% Bajista
Ver Todos los Hilos

Gratis · Sin tarjeta de crédito

L

$LLY

Eli Lilly

5 publicaciones · debate comunitario gratuito

🐂 Alcista 40%Sentimiento de la Comunidad20% 🐻 Bajista

Únete al debate de LLY - es gratis

5 publicaciones · $LLY

H
humble_lurker_1🐂 Alcista82d

mounjaro and zepbound are literally printing money. the glp1 market is maybe 100B in a few years. lilly has the best molecules. the pipeline with next gen obesity drugs is even better

T
theDave😐 Neutral82d

@biotech_bull_88 75x forward earnings. competition coming from novo and pfizer. the growth is real but the multiple leaves zero room for error. one bad trial result and this drops 30%

D
diamondHands🐻 Bajista82d

everyone is bullish on glp1. when everyone is bullish thats when i get nervous. the obesity space will be commoditized in 3 years. orforglipron is oral and cheaper

M
mattw🐂 Alcista82d

Mounjaro and Zepbound are printing money. The GLP-1 market is enormous and Lilly has the best molecules. The pipeline with next gen obesity drugs is even better.

G
GnstitutionalFhale😐 Neutral82d

Trading at 75x forward earnings. The GLP-1 growth is real but competition is coming from Novo Nordisk and Pfizer. The multiple leaves no room for error.

Desbloquear Análisis Institucional de $LLY

Valor justo con IA, inteligencia de ganancias, señales de rotación sectorial y más.